The first phase of the ibogaine dream-state takes place during the initial onset of small doses of ibogaine Hydrochloride given to a patient as pre-withdrawal symptoms appear. These microdoses of ibogaine evoke Rapid Eye Movement activity alongside an auditory buzzing that stems from cellular resonation in the left and right hemispheres of the opiate user’s brain.
These smaller doses of ibogaine eventually compound, producing visionary activity and monologic narration that may focus on repressed emotional memories stemming from childhood and beyond.
During the reflective phase of the ibogaine experience, a patient’s focused attention shifts towards the solar plexus and begins processing emotion and memory. For many people, the visionary elements fade somewhat during this phase, and emotional intelligence is accessed in which personal realizations are felt more than watched or witnessed.
Although somewhat subtle when compared with the visual activity experienced during the beginning phase of ibogaine dosing, this second stage is equally engaging in its way. It often produces a renaissance of emotional resolutions, therapeutically healing the scars of the past.
This initial timeframe will follow by a melancholy period commonly referred to as the “grey day” which lasts from 8 to 12 hours and begins about 12 -18 hours after processing the initial doses of ibogaine HCl.
Following the grey day, a renaissance period unfolds, unleashing a significant increase in beta-endorphins. This endorphin release is coupled with the beneficial result of GDNF support in the brain. This GDNF release alongside ibogaine’s potentiating effect on the NMDA receptor therapeutically resets many of the brain’s signaling networks greatly benefit those who have reprogrammed their neurological state with daily use of opiates or opioid medications.